Back to results
US 2026/0137657 A1Published application
Methods and compositions for treating glucocorticoid excess
AssigneeSparrow Pharmaceuticals, Inc.
InventorDavid A. Katz
Life of this patent
Estimating the term…
Abstract
The disclosure provides a method of treatment for glucocorticoid excess in a patient in need thereof, comprising administering to the patient a pseudo-irreversible HSD-1 inhibitor.
Claims18
A composition suitable for treating diabetes and lowering intracellular cortisol level in a human patient with diabetes and an elevated level of cortisol, comprising a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:
- wherein the therapeutically effective amount of the compound, or the pharmaceutically acceptable salt thereof, is about 0.2 mg to about 40 mg daily,
- wherein administration of the compound, or a pharmaceutically acceptable salt thereof, decreases the patient's hemoglobin A1c (HbA1c) levels compared to the patient's HbA1c levels before the compound is initially administered to the patient, and
- wherein the compound does not show tachyphylaxis for HSD-1 inhibition in human adipose tissue.
Dependencies are inferred from the claim text.